Bellevue Group AG Has $916,000 Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Bellevue Group AG increased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 92.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,718 shares of the company's stock after purchasing an additional 11,372 shares during the quarter. Bellevue Group AG's holdings in Protagonist Therapeutics were worth $916,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of Montreal Can lifted its stake in shares of Protagonist Therapeutics by 4.5% in the 4th quarter. Bank of Montreal Can now owns 6,250 shares of the company's stock valued at $241,000 after purchasing an additional 270 shares during the last quarter. Maryland State Retirement & Pension System boosted its stake in shares of Protagonist Therapeutics by 1.4% during the 4th quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company's stock worth $779,000 after acquiring an additional 278 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Protagonist Therapeutics by 10.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after acquiring an additional 295 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Protagonist Therapeutics by 1.1% in the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company's stock valued at $1,112,000 after acquiring an additional 300 shares in the last quarter. Finally, KBC Group NV lifted its holdings in Protagonist Therapeutics by 54.4% in the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after purchasing an additional 737 shares during the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics Stock Down 2.0 %

PTGX traded down $0.88 during trading on Friday, reaching $43.04. 671,228 shares of the company's stock were exchanged, compared to its average volume of 869,376. Protagonist Therapeutics, Inc. has a fifty-two week low of $26.79 and a fifty-two week high of $60.60. The company has a market capitalization of $2.67 billion, a P/E ratio of 16.18 and a beta of 2.65. The business has a 50 day moving average price of $46.87 and a 200 day moving average price of $42.75.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.31. The business had revenue of $28.32 million for the quarter, compared to analysts' expectations of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. As a group, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. JMP Securities reissued a "market outperform" rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research report on Friday, February 7th. BMO Capital Markets raised their price target on Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. BTIG Research set a $73.00 price objective on Protagonist Therapeutics in a research note on Monday, March 3rd. The Goldman Sachs Group decreased their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a research note on Monday, February 24th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a research report on Friday, March 28th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $65.44.

Insider Buying and Selling

In other Protagonist Therapeutics news, Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the transaction, the director now owns 13,130 shares of the company's stock, valued at approximately $712,302.50. The trade was a 23.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the business's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the sale, the chief executive officer now owns 540,260 shares in the company, valued at approximately $20,627,126.80. This trade represents a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,532 shares of company stock worth $3,665,786 in the last quarter. 5.40% of the stock is owned by corporate insiders.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.